Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2000242 | PMC |
| http://dx.doi.org/10.1136/gut.2007.126144 | DOI Listing |
Publication Analysis
Top Keywords
treatment atazanivir
4
atazanivir associated
4
associated grade
4
grade hyperbilirubinaemia
4
hyperbilirubinaemia efavirenz
4
treatment
1
associated
1
grade
1
hyperbilirubinaemia
1
efavirenz
1
Similar Publications
Pharmacokinetic properties and tolerability of bevirimat and atazanavir in healthy volunteers: an open-label, parallel-group study.
Clin Ther
October 2008
Panacos Pharmaceuticals Inc., Gaithersburg, Maryland 20877, USA.
Background: Bevirimat, an inhibitor of HIV-1 maturation, is currently in clinical development for the treatment of HIV-1 infection. It undergoes glucuronidation via uridine diphosphate glucuronosyltransferases (UGTs). The protease inhibitor atazanavir is a potent inhibitor of UGT1A1.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!